Theradiag (Alternext: ALTER) is a pioneer in the field of the development, manufacture and sale of high quality innovative IVD (in vitro diagnostic) products. Relying on this 25 years long expertise, Theradiag is currently focusing its development strategy on theranostic tests to monitor biotherapies. Theranostics is an emerging branch of in vitro diagnostics, whose purpose is to provide information that allows the greatest possible customisation of treatment. Theranostic tests are thus associated with a targeted biotherapy to predict or assess the patient’s response by measuring one or several biomarkers.
Dr Philippe Pouletty and Antoine Pau are Board members.